Plasma F2-isoprostanes and coronary artery calcification: The CARDIA study

Clinical Chemistry

Volumn 51, Issue 1, 2005, Pages 125-131

  Gross, Myron ^a   Steffes, Michael ^a   Jacobs Jr , David R ^b,e   Yu, Xinhua ^b   Lewis, Linda ^a   Lewis, Cora E ^c   Loria, Catherine M ^d  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c University of Alabama at Birmingham   (United States)

^d NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^e UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; FREE RADICAL; ISOPROSTANE; PROSTAGLANDIN F2; PROSTAGLANDIN SYNTHASE; ISOPROSTANE DERIVATIVE;

ADOLESCENT; ADULT; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; BODY MASS; CALCIFICATION; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; CORONARY ARTERY CALCIFICATION; CORONARY ARTERY DISEASE; DIET SUPPLEMENTATION; DISEASE ACTIVITY; EARLY DIAGNOSIS; FEMALE; GAS CHROMATOGRAPHY; HUMAN; LIPID OXIDATION; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; SCORING SYSTEM; AGE; BIOLOGICAL MODEL; BLOOD; CALCINOSIS; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY BLOOD VESSEL; PATHOLOGY; SEX DIFFERENCE;

ADOLESCENT; ADULT; AGE FACTORS; CALCINOSIS; CORONARY ARTERIOSCLEROSIS; CORONARY VESSELS; F2-ISOPROSTANES; FEMALE; HUMANS; MALE; MODELS, CARDIOVASCULAR; SEX FACTORS;

EID: 11144285386     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2004.037630     Document Type: Article

References (40)

1. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989;320:915-24.
2. Parthasarathy S, Santanam N, Ramachandran S, Meilhac O. Oxidants and antioxidants in atherogenesis. An appraisal. J Lipid Res 1999;40:2143-57.
3. Stringer MD, Gorog PG, Freeman A, Kakkar W. Lipid peroxides and atherosclerosis. BMJ 1989;298:281-4.
4. Salonen JT, Yla-Herttuala S, Yamamoto R, Butler S, Korpela H, Salonen R, et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 1992;339:883-7.
5. Kushi LH, Folsom AR, Prineas RJ, Mink PJ, Wu Y, Bostick RM. Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. N Engl J Med 1996;334:1156-62.
6. Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med 1993;328:1444-9.
7. The effect of vitamin E and β carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med 1994;330:1029-35.
8. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:154-60.
9. Roberts LJ, Morrow JD. Isoprostanes as markers of lipid peroxidation in atherosclerosis. In: Serham CN, Ward PA, eds. Molecular and cellular basis of inflammation. Totowa, NJ: Humana Press, 1999:141-63.
10. Morrow JD, Chen Y, Brame CJ, Yang J, Sanchez SC, Xu J, et al. The isoprostanes: unique prostaglandin-like products of free-radical-initiated lipid peroxidation. Drug Metab Rev 1999;31:117-39.
11. Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ 2nd. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Nati Acad Sci U S A 1990;87:9383-7.
12. McCall MR, Frei B. Can antioxidant vitamins materially reduce oxidative damage in humans? Free Radic Biol Med 1999;26: 1034-53.
13. Morrow JD, Frei B, Longmire AW, Gaziano JM, Lynch SM, Shyr Y, et al. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N Engl J Med 1995;332:1198-203.
14. Friedman GD, Cutter GR, Donahue RP, Hughes GH, Hulley SB, Jacobs DR Jr, et al. CARDIA: study design, recruitment, and some characteristics of the examined subjects. J Clin Epidemiol 1988; 41:1105-16.
15. Jacobs DR Jr, Hannan PJ, Wallace D, Liu K, Williams OD, Lewis CE. Interpreting age, period and cohort effects in plasma lipids and serum insulin using repeated measures regression analysis: the CARDIA Study. Stat Med 1999;18:655-79.
16. Smith DE, Thompson JK, Raczynski JM, Hilner JE. Body image among men and women in a biracial cohort: the CARDIA Study. Int J Eat Disord 1999;25:71-82.
17. Davidson K, Jonas BS, Dixon KE, Markovitz JH. Do depression symptoms predict early hypertension incidence in young adults in the CARDIA study? Coronary Artery Risk Development in Young Adults. Arch Intern Med 2000;160:1495-500.
18. Warnick GR. Enzymatic methods for quantification of lipoprotein lipids. Methods Enzymol 1986;129:101-23.
19. Warnick GR, Benderson J, Albers JJ. Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Clin Chem 1982;28:1379-88.
20. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
21. Macy EM, Hayes TE, Tracy RP. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem 1997;43: 52-8.
22. Gross M, Yu X, Hannan P, Prouty C, Jacobs DR Jr. Lipid standardization of serum fat-soluble antioxidant concentrations: the YALTA study. Am J Clin Nutr 2003;77:458-66.
23. Morrow JD, Roberts LJ 2nd. Mass spectrometric quantification of F2-isoprostanes in biological fluids and tissues as measure of oxidant stress. Methods Enzymol 1999;300:3-12.
24. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990;15:827-32.
25. Sangiorgi G, Rumberger JA, Severson A, Edwards WD, Gregoire J, Fitzpatrick LA, et al. Arterial calcification and not lumen stenosis is highly correlated with atherosclerotic plaque burden in humans: a histologic study of 723 coronary artery segments using nondecalcifying methodology. J Am Coll Cardiol 1998;31:126-33.
26. Morrow JD, Awad JA, Kato T, Takahashi K, Badr KF, Roberts LJ 2nd, et al. Formation of novel non-cyclooxygenase-derived prostanoids (F2-isoprostanes) in carbon tetrachloride hepatotoxicity. An animal model of lipid peroxidation. J Clin Invest 1992;90:2502-7.
27. Awad JA, Morrow JD, Hill KE, Roberts LJ 2nd, Burk RF. Detection and localization of lipid peroxidation in selenium- and vitamin E-deficient rats using F2-isoprostanes. J Nutr 1994;124:810-6.
28. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, et al. Chlamydia pneumoniae IgG titres and coronary heart disease: prospective study and meta-analysis. BMJ 2000;321:208-13.
29. Meng S, Roberts U 2nd, Cason GW, Curry TS, Manning RD, Jr. Superoxide dismutase and oxidative stress in Dahl salt-sensitive and -resistant rats. Am J Physiol Regul Integr Comp Physiol 2002;283:R732-8.
30. Cracowski JL, Carpentier PH, Imbert B, Cachot S, Stanke-Labesque F, Bessard J, et al. Increased urinary F2-isoprostanes in systemic sclerosis, but not in primary Raynaud's phenomenon: effect of cold exposure. Arthritis Rheum 2002;46:1319-23.
31. Cheng YJ, Church TS, Kimball TE, Nichaman MZ, Levine BD, McGuire DK, et al. Comparison of coronary artery calcium detected by electron beam tomography in patients with to those without symptomatic coronary heart disease. Am J Cardiol 2003; 92:498-503.
32. Newman AB, Naydeck BL, Sutton-Tyrrell K, Feldman A, Edmundowicz D, Kuller LH. Coronary artery calcification in older adults to age 99: prevalence and risk factors. Circulation 2001;104:2679-84.
33. Rumberger JA, Sheedy PF 2nd, Breen JF, Fitzpatrick LA, Schwartz RS. Electron beam computed tomography and coronary artery disease: scanning for coronary artery calcification. Mayo Clin Proc 1996;71:369-77.
34. Kennedy J, Shavelle R, Wang S, Budoff M, Detrano RC. Coronary calcium and standard risk factors in symptomatic patients referred for coronary angiography. Am Heart J 1998;135:696-702.
35. Secci A, Wong N, Tang W, Wang S, Doherty T, Detrano R. Electron beam computed tomographic coronary calcium as a predictor of coronary events: comparison of two protocols. Circulation 1997; 96:1122-9.
36. Block G, Dietrich M, Norkus EP, Morrow JD, Hudes M, Caan B, et al. Factors associated with oxidative stress in human populations. Am J Epidemiol 2002;156:274-85.
37. Roeters van Lennep JE, Westerveld HT, Erkelens DW, van der Wall EE. Risk factors for coronary heart disease: implications of gender. Cardiovasc Res 2002;53:538-49.
38. Kannel WB, D'Agostino RB, Belanger AJ. Fibrinogen, cigarette smoking, and risk of cardiovascular disease: insights from the Framingham Study. Am Heart J 1987;113:1006-10.
39. Brown SA, Hutchinson R, Morrisett J, Boerwinkle E, Davis CE, Gotto AM Jr, et al. Plasma lipid, lipoprotein cholesterol, and apoprotein distributions in selected US communities. The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb 1993;13:1139-58.
40. Mosca L, Grundy SM, Judelson D, King K, Limacher M, Oparil S, et al. Guide to preventive cardiology for women. AHA/ACC Scientific Statement Consensus panel statement. Circulation 1999;99: 2480-4.